🇺🇸 FDA
Pipeline program

COYA 302

C302-CLN-2301

Phase 2 small_molecule active

Quick answer

COYA 302 for Amyotrophic Lateral Sclerosis (ALS) is a Phase 2 program (small_molecule) at Coya Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Coya Therapeutics
Indication
Amyotrophic Lateral Sclerosis (ALS)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials